Nasal vaccination with poly(beta-amino ester)-poly(D,L-lactide-co-lycolide) hybrid nanoparticles

Basit Öğe Kaydı
dc.contributor.authorSinani, Genada
dc.contributor.authorSessevmez, Melike
dc.contributor.authorGök, M. Koray
dc.contributor.authorÖzgümüş, Saadet
dc.contributor.authorOkyar, Alper
dc.contributor.authorAlpar, H. Oya
dc.contributor.authorCevher, Erdal
dc.date.accessioned2021-05-15T12:43:00Z
dc.date.available2021-05-15T12:43:00Z
dc.date.issued2017
dc.departmentEczacılık Fakültesien_US
dc.descriptionCevher, Erdal/0000-0002-0486-2252; OZGUMUS, SAADET/0000-0002-1793-0859; GOK, MEHMET KORAY/0000-0003-2497-9359
dc.description.abstractMucosal vaccination stimulates both mucosal and systemic immunity. However, mucosal applications of vaccine antigens in their free form generally result in poor systemic immune responses and need adjuvantation. In this study, bovine serum albumin loaded, new hybridised poly(beta-amino ester)-poly( D, Llactide-co-glycolide) nanoparticles were prepared by double emulsion-solvent evaporation method, characterised and evaluated in vivo as nasal vaccine carriers. Cationic spherical particles with a mean size of 240 nm, good physical stability and high encapsulation efficiency were obtained. Protein structure was not affected throughout preparation and minimal toxicity was shown in Calu-3 and A549 cells. Nasal vaccination with these nanoparticles revealed markedly higher humoral immune responses compared with free antigen following intranasal and subcutaneous immunisation. Mucosal immune response was also stimulated and cytokine titres indicated that Th1 and Th2 pathways were successfully activated. This study shows that the formulated hybrid nanoparticles can be a promising carrier for nasal immunisation of poor antigenic proteins. (C) 2017 Elsevier B.V. All rights reserved.en_US
dc.description.sponsorshipScientific Research Projects Coordination Unit of Istanbul UniversityIstanbul University [36160]; Scientific and Technological Research Council of Turkey (TUBITAK)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)en_US
dc.description.sponsorshipThis work was supported by Scientific Research Projects Coordination Unit of Istanbul University, Project Number: 36160. Genada Sinani acknowledges The Scientific and Technological Research Council of Turkey (TUBITAK) for the PhD Fellowship Program.en_US
dc.identifier.doi10.1016/j.ijpharm.2017.06.053
dc.identifier.endpage14en_US
dc.identifier.issn0378-5173
dc.identifier.issn1873-3476
dc.identifier.issue1-2en_US
dc.identifier.pmid28629979
dc.identifier.scopus2-s2.0-85021155541
dc.identifier.scopusqualityQ1
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.1016/j.ijpharm.2017.06.053
dc.identifier.urihttps://hdl.handle.net/20.500.12939/996
dc.identifier.volume529en_US
dc.identifier.wosWOS:000408009200001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorSinani, Genada
dc.institutionauthorAlpar, H. Oya
dc.language.isoen
dc.publisherElsevier Science Bven_US
dc.relation.ispartofInternational Journal of Pharmaceutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMucosal Vaccinationen_US
dc.subjectNasal Deliveryen_US
dc.subjectNanoparticleen_US
dc.subjectPoly(Beta-Amino Ester)en_US
dc.subjectPoly(D,L-Lactide-Co-Glycolide)en_US
dc.subjectAntibodyen_US
dc.subjectCytokineen_US
dc.titleNasal vaccination with poly(beta-amino ester)-poly(D,L-lactide-co-lycolide) hybrid nanoparticles
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Eczacılık Fakültesi Yayın Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu